在高度流行的美国人口中,多发性硬化症治疗模式的转变
Sue Kwon1, Stefan Sillau2, John R Corboy2
1Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, Aurora, Colorado, USA.
Annals of clinical and translational neurology
|April 24, 2024
概括
多发性硬化症 (MS) 在科罗拉多州非常普遍. 用疾病修饰疗法治疗,特别是高效疗法,显著增加,反映了MS护理的进步.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 多发性硬化症 (MS) 是一种慢性自身免疫性疾病,影响中枢神经系统.
- 了解MS的患病率和治疗模式对于资源分配和医疗保健规划至关重要.
研究的目的:
- 确定科罗拉多州代表性人口中患有多发性硬化症 (MS) 个体的患病率和人口统计特征.
- 评估这种多发性硬化队列中疾病修饰疗法 (DMT) 的使用情况.
主要方法:
- 使用科罗拉多大学卫生系统 (2012-2020) 的数据进行了回顾性观察性研究.
- 使用MS流行工作组算法计算的流行率,按人口统计学分层.
- 通过链接索赔数据分析的DMT利用率,按疗效分类 (高度有效与中度有效).
主要成果:
- 截至2020年12月31日,每10万名多发性硬化症患者中经过年龄调整的患病率为572.3.
- 在人口统计学子组中,患病率各不相同,在西班牙裔男性,白人女性和黑人女性中存在显著差异.
- 总体DMT暴露率为62.4%,随着时间的推移,高效疗法的使用趋势越来越大.
结论:
- 多发性硬化症在研究的科罗拉多州人口中非常普遍.
- 观察到DMT总体使用量和高效疗法比例的显著增加.
- 高效疗法使用的增加,特别是抗CD20疗法,表明MS管理策略的转变.
相关概念视频
01:28Drug Therapy
43
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
43
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183